Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA6 | Q9UK32 | 2/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PLK1 | P53350 | 1/20 | 0.30 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20740484 | 0.88 | RPS6KA6 (0.35) | RPS6KA6PIK3CA | |
| SCHEMBL20740503 | 0.80 | ALDH1A1 (0.33) | RPS6KA6 | |
| SCHEMBL20740476 | 0.79 | ALDH1A1 (0.33) | RPS6KA6 | |
| SCHEMBL20740438 | 0.78 | RPS6KA6 (0.32) | RPS6KA6 | |
| SCHEMBL20768350 | 0.78 | RPS6KA6 (0.32) | RPS6KA6 | |
| SCHEMBL27196797 | 0.73 | PIK3CD (0.38) | RPS6KA6 | |
| SCHEMBL20740491 | 0.70 | MARK3 (0.40) | RPS6KA6 | |
| SCHEMBL20740467 | 0.70 | MARK3 (0.35) | RPS6KA6 | |
| SCHEMBL20740490 | 0.70 | MARK3 (0.35) | RPS6KA6 | |
| SCHEMBL20740437 | 0.69 | CCNE1 (0.35) | RPS6KA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3444254-B1 | HETEROCYCLIC-SUBSTITUTED PYRIDINOPYRIMIDINONE DERIVATIVE AS CDK INHIBITOR AND USE THEREOF | SHANGHAI XUNHE PHARMACEUTICAL TECH CO LTD (CN) | 2020-05-13 | — | — | EP | disclosed |
| US-10351578-B2 | Heterocyclic-substituted pyridinopyrimidinone derivative as CDK inhibitor and use thereof | Shanghai Xunhe Pharmaceutical Technology Co. Ltd. (CN) | 2019-07-16 | — | — | US | disclosed |
| US-20190071453-A1 | Heterocyclic-substituted Pyridinopyrimidinone Derivative as CDK Inhibitor and Use thereof | CHENGDU JINRUI FOUNDATION BIOTECH CO., LTD. (CN) | 2019-03-07 | — | — | US | disclosed |
| EP-3444254-A1 | HETEROCYCLIC-SUBSTITUTED PYRIDINOPYRIMIDINONE DERIVATIVE AS CDK INHIBITOR AND USE THEREOF | Shanghai Xunhe Pharmaceutical Technology Co., Ltd. (CN) | 2019-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071453-A1 | Heterocyclic-substituted Pyridinopyrimidinone Derivative as CDK Inhibitor and Use thereof | CDK4, CDK6, CCNI | RPS6KA6 182/4885PIK3CA 119/4885PLK1 73/4885 |
| US-10351578-B2 | Heterocyclic-substituted pyridinopyrimidinone derivative as CDK inhibitor and use thereof | CDK4, CDK6, CCNI | RPS6KA6 182/4885PIK3CA 119/4885PLK1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.